Nanomedicine has become an effective approach to treating metabolic and inflammatory diseases, enhancing drug responsiveness, specificity, and therapeutic effectiveness. This paper documents the strategies used to formulate and use dual-loaded nanocarriers to deliver, in combination, reactive oxygen species (ROS) scavengers and anti-inflammatory agents. Agents already in common use, including curcumin, dexamethasone, resveratrol, and non-steroidal anti-inflammatory drugs (NSAIDs), have been shown to have better performance with nanoformulation treatments, since they achieve better solubility, form durability, and controlled release characteristics. Different nanocarrier formats: liposomes, core-shell nanoparticles, polymeric micelles, layer-by-layer constructs, etc., can be used to provide simultaneous or sequential delivery, leading to a possible synergistic interaction and optimal therapeutic effect. Sequential release forms have been found to have great potential when they can modulate oxidative stress, provide anti-inflammatory therapy, and thereby maximise efficacy. Even though it has been shown that dual-loaded nanocarriers are promising, there are significant obstacles to their stability, scalability, and regulatory approval. Challenges related to nanoparticle aggregation, early release of the drug, and complicated manufacturing procedures prevent the wide use in clinical practice. Moreover, heavy quality control, as well as dynamic regulatory paths, proves to be another impediment. Future directions include the creation of intelligent, stimuli-responsive nanocarriers which can release their contents in an on-demand, target-specific manner in response to physiological or environmental stimuli, as well as a customized approach to nanomedicine based on individual patient characteristics. These advances have the potential to make nanotherapeutics into specific, flexible, and disease-personalized therapies. Future research and interdisciplinary collaboration will be essential to eliminate recent shortcomings and the clinical translation of nanomedicine.